Recently, increased attention has been given to the development of radioligand therapy (RLT) using radiopharmaceuticals targeting the prostate-specific membrane antigen (PSMA) [3], a target commonly overexpressed in prostate cancer and whose expression increases with disease progression [4]. This evidence concerns the gene FOLH1 and prostate cancer.